Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats.

Yamazaki T, Izumi Y, Nakamura Y, Yamashita N, Fujiki H, Osada-Oka M, Shiota M, Hanatani A, Shimada K, Iwao H, Yoshiyama M.

Circ Heart Fail. 2012 Nov;5(6):794-802. doi: 10.1161/CIRCHEARTFAILURE.112.968750.

2.

Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats.

Yamazaki T, Nakamura Y, Shiota M, Osada-Oka M, Fujiki H, Hanatani A, Shimada K, Miura K, Yoshiyama M, Iwao H, Izumi Y.

J Pharmacol Sci. 2013 Sep 20;123(1):58-66.

3.

Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.

Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, Aizawa Y.

Biochem Pharmacol. 2008 Mar 15;75(6):1322-30. doi: 10.1016/j.bcp.2007.11.011.

PMID:
18179782
4.

A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.

Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, O'Brien T, Zimmer C, Orlandi C, Konstam MA.

J Card Fail. 2011 Dec;17(12):973-81. doi: 10.1016/j.cardfail.2011.08.005.

PMID:
22123358
5.

Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.

Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK.

J Card Fail. 2011 Dec;17(12):982-9. doi: 10.1016/j.cardfail.2011.08.012.

PMID:
22123359
6.

Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure.

Milliez P, Messaoudi S, Nehme J, Rodriguez C, Samuel JL, Delcayre C.

Am J Physiol Heart Circ Physiol. 2009 Feb;296(2):H435-41. doi: 10.1152/ajpheart.00591.2008.

7.

Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.

Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y.

Biochem Pharmacol. 2007 Nov 15;74(10):1466-75.

PMID:
17720144
8.

Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.

Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.

Cardiovasc Drug Rev. 2007 Spring;25(1):1-13. Review.

PMID:
17445084
9.

Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction.

Wada K, Tahara A, Arai Y, Aoki M, Tomura Y, Tsukada J, Yatsu T.

Eur J Pharmacol. 2002 Aug 23;450(2):169-77.

PMID:
12206855
10.

Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction.

Huang BS, White RA, Ahmad M, Tan J, Jeng AY, Leenen FH.

Cardiovasc Res. 2009 Feb 15;81(3):574-81. doi: 10.1093/cvr/cvn222.

11.

Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.

Morooka H, Iwanaga Y, Tamaki Y, Takase T, Akahoshi Y, Nakano Y, Fujiki H, Miyazaki S.

Circ Heart Fail. 2012 Jul 1;5(4):484-92. doi: 10.1161/CIRCHEARTFAILURE.111.965392.

12.

Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats.

Shimada T, Yoshiyama M, Takeuchi K, Omura T, Takemoto Y, Kim S, Iwao H, Yoshikawa J.

Cardiovasc Res. 1998 Mar;37(3):618-26.

13.

Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure.

Ishikawa M, Kobayashi N, Sugiyama F, Onoda S, Ishimitsu T.

Int Heart J. 2013;54(2):98-106.

14.

Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure.

Wada K, Fujimori A, Matsukawa U, Arai Y, Sudoh K, Yatsu T, Sasamata M, Miyata K.

Eur J Pharmacol. 2005 Jan 10;507(1-3):145-51.

PMID:
15659304
15.

Effects of a DA2/alpha2 agonist and a beta1-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusion.

Masson S, Masseroli M, Fiordaliso F, Calvillo L, D'Aquila S, Bernasconi R, Garrido G, Torri M, Razzetti R, Bongrani S, Latini R.

J Cardiovasc Pharmacol. 1999 Sep;34(3):321-6.

PMID:
10470987
16.

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.

Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators..

Circulation. 2003 Jun 3;107(21):2690-6.

17.

Chronic vasopressin V(1A) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats.

Van Kerckhoven R, Lankhuizen I, van Veghel R, Saxena PR, Schoemaker RG.

Eur J Pharmacol. 2002 Aug 2;449(1-2):135-41.

PMID:
12163117
18.

Macrophage colony-stimulating factor treatment after myocardial infarction attenuates left ventricular dysfunction by accelerating infarct repair.

Yano T, Miura T, Whittaker P, Miki T, Sakamoto J, Nakamura Y, Ichikawa Y, Ikeda Y, Kobayashi H, Ohori K, Shimamoto K.

J Am Coll Cardiol. 2006 Feb 7;47(3):626-34.

19.

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA.

J Card Fail. 2005 May;11(4):260-9.

PMID:
15880334
20.

Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.

Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, Sugiura E, Kumagai N, Nakamori S, Nakajima H, Hoshino K, Machida H, Okamoto S, Onishi K, Nakamura M, Nobori T, Ito M.

J Cardiol. 2012 Dec;60(6):462-9. doi: 10.1016/j.jjcc.2012.09.002.

Items per page

Supplemental Content

Support Center